Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing.
Ibandronate is a highly potent, nitrogen-containing bisphosphonate. Unlike most other bisphosphonates, it is under clinical development for both oral and intravenous (i.v.) administration. Ibandronate can be used in convenient intermittent regimens that may optimize therapeutic outcome with enhanced...
Main Authors: | Bauss, F, Russell, R |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2004
|
Similar Items
-
Intermittent intravenous ibandronate therapy for osteoporosis
by: L I Alekseeva, et al.
Published: (2008-09-01) -
Ibandronate: pharmacology and preclinical studies.
by: Russell, R
Published: (2006) -
A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate.
by: Reginster, J, et al.
Published: (2006) -
Efficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosis.
by: Cooper, C, et al.
Published: (2003) -
Efficiency of Ibandronate in Monotherapy and in Combination with Alfacalcidol in Women with Postmenopausal Osteoporosis
by: S.I. Ismailov, et al.
Published: (2016-09-01)